CJC-1295 DAC vs No DAC: Key Differences Explained

CJC-1295 with DAC vs no DAC (Mod GRF 1-29): what the linker does, half-life evidence, what human studies measured, and safety questions.

Signal IQ Editorial5 min read · Updated Nov 8, 2026
CJC-1295 DAC vs No DAC: Key Differences Explained
In this article
  1. CJC-1295 with DAC vs no DAC: how they compare
  2. What is MOD GRF 1-29?
  3. What does DAC do, and how long does CJC-1295 last?
  4. What the human studies actually showed
  5. CJC-1295 no DAC with ipamorelin
  6. CJC-1295 side effects
  7. Questions worth asking a clinician
  8. Frequently asked questions
  9. References

When people compare CJC-1295 DAC vs no DAC, they are comparing two separate compounds that happen to be sold under one label. Each is an engineered piece of GHRH, the hypothalamic signal for growth hormone. Only the DAC form has a chemical hook that holds it onto albumin, so it persists for days. The no-DAC form, usually called Mod GRF 1-29, clears quickly.

Key takeaways
  • DAC means Drug Affinity Complex, a reactive group that lets the peptide latch onto albumin in the bloodstream.
  • Healthy volunteers given the DAC form showed an estimated half-life of roughly 6 to 8 days. Nobody has published a measured human half-life for the no-DAC form.
  • Almost every human study used the DAC form and tracked hormone concentrations, not muscle, fat or recovery.
  • Regulators have not approved either one, and anti-doping rules ban both.

CJC-1295 with DAC vs no DAC: how they compare

FeatureWith DACNo DAC (Mod GRF 1-29)
Peptide coreFirst 29 residues of GHRH, four altered for stabilityIdentical core
Albumin attachmentPresent, via a maleimide groupAbsent
Human half-life dataAbout 5.8 to 8.1 days, healthy adultsNo published measurement
Human researchTwo placebo-controlled trials plus a study of overnight GH rhythmNo trial located under this name
Outcomes trackedGrowth hormone and IGF-1 concentrationsNothing published in people
US regulatory positionUnapprovedUnapproved
Anti-dopingBanned in and out of competitionBanned as a GHRH analogue

Because a vial marked simply “CJC-1295” does not reveal which one it holds, the paperwork matters. Our guide to reading a peptide COA explains what to check.

What is MOD GRF 1-29?

Mod GRF 1-29 is the usual nickname for the version without DAC. It keeps the stabilised 29-residue GHRH sequence but lacks any albumin-binding group, so it is expected to be broken down and cleared fast. Naming is inconsistent across the market: “modified GRF 1-29” and “CJC-1295 no DAC” refer to the same thing.

Literature searches turned up no human clinical trial of it under any of these names.

What does DAC do, and how long does CJC-1295 last?

The DAC group is a reactive maleimide that attaches to one particular spot on albumin, the most plentiful protein in plasma. Riding on albumin shields the peptide from fast clearance. In rats, the conjugate was still present a full day later, and the peptide itself could be detected after three days.

CJC-1295 DAC half-life

For the DAC form in healthy adults, Teichman and colleagues (2006) estimated a half-life between 5.8 and 8.1 days. Numbers quoted for the no-DAC form on forums are not trial measurements. For why this parameter matters, read the peptide half-life guide.

What the human studies actually showed

  • Dose-escalation trials: Two randomised, double-blind, placebo-controlled studies, lasting 28 and 49 days, enrolled healthy volunteers aged 21 to 61. A single dose lifted average GH by two to ten times over at least six days and IGF-1 by 1.5 to 3 times for roughly nine to eleven days. Authors reported no serious adverse reactions.
  • Overnight sampling study: In healthy young men, the size and number of GH pulses stayed the same one week after one injection. What moved was the baseline: lowest GH values climbed about 7.5-fold, with averages up 46% for GH and 45% for IGF-1. In effect, the long-acting form lifted the floor instead of flattening the peaks.
  • Efficacy trial: A phase 2 study in HIV-related visceral obesity was registered and later marked terminated, with no results released.

No study measured muscle gain, strength, fat loss, sleep or recovery. The trials were short, small, and designed to answer a pharmacology question.

CJC-1295 no DAC with ipamorelin

The no-DAC form is the one most often paired with ipamorelin. The reasoning is that a GHRH analogue and a ghrelin-receptor agonist reach the pituitary by separate routes. Human data on the pairing are sparse.

Signal IQ’s CJC-1295 + ipamorelin page reports a research range from 500 mcg of each compound up to 1 mg of each, taken once a day in the evening by subcutaneous injection, fasted, from a 5 mg/5 mg vial, over cycles of 12 to 16 weeks with 2 to 4 weeks off. These are ranges seen in research protocols, not advice, and a qualified clinician should be involved. More in the CJC-1295 and ipamorelin stack article.

CJC-1295 side effects

The early trials found the DAC form reasonably well tolerated, with no serious reactions, but they followed healthy people for only weeks, so long-term effects are unknown.

FDA’s page on compounded CJC-1295 raises concerns about immune reactions, impurities, and serious events such as faster heart rate and a body-wide blood vessel dilation reaction, and says clinical information is limited. Across growth hormone-axis peptides in general, people report fluid retention, shifts in prolactin and cortisol, appetite changes, blood sugar effects, aches and injection-site irritation. That is a class-wide list, not proof that each effect belongs to CJC-1295. See peptide side effects.

Note: Neither version is a licensed drug. Both appear on the WADA list of growth hormone-releasing factors that tested athletes may never use. A “for research use” label is not a regulatory endorsement. See research use vs human use.

Questions worth asking a clinician

  • Is there any clinical reason to alter GH or IGF-1 in the first place?
  • How would existing conditions, medicines and lab results change the risk? The Bloodwork Panel Planner helps organise baseline tests.
  • Which molecule is in the vial, DAC or not?

Related pathways are compared in ipamorelin vs sermorelin vs tesamorelin, or ask Pulse.

Frequently asked questions

How does CJC-1295 with DAC differ from CJC-1295 without DAC?

The DAC form carries an albumin-binding group that stretches its action to about a week. Without it, the peptide acts briefly.

Are Mod GRF 1-29 and CJC-1295 one and the same?

Mod GRF 1-29 normally refers to the no-DAC version, but sellers label loosely, so a product named only “CJC-1295” could be either.

Does the long-acting form flatten natural GH pulses?

In the single study that looked, pulses kept their size and rhythm while the baseline between them rose.

Can CJC-1295 add muscle or reduce fat?

That is unproven. Published human work tracked hormone levels for weeks, not body composition.

Has FDA cleared CJC-1295?

No, neither version. The agency has flagged safety questions about compounded product.

References

  1. Teichman et al., J Clin Endocrinol Metab, 2006 (CJC-1295 in healthy adults, GH and IGF-I response) — pubmed.ncbi.nlm.nih.gov
  2. Ionescu and Frohman, J Clin Endocrinol Metab, 2006 (GH pulses under CJC-1295) — pubmed.ncbi.nlm.nih.gov
  3. Jetté et al., Endocrinology, 2005 (albumin bioconjugate design of CJC-1295) — pubmed.ncbi.nlm.nih.gov
  4. ClinicalTrials.gov NCT00267527 — clinicaltrials.gov

Go deeper on Signal IQ

Dosing & protocolCJC-1295 + IpamorelinResearch profileCJC-1295 / Ipamorelin

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading